FDA
29th July 2019

FDA Advisory Committee in Favor of Mannitol Inhalation Powder

On May 8th, 2019 the Pulmonary-Allergy Drugs Advisory Committee (PADAC) convened to review the new drug application (NDA)

FDA Advisory Committee in Favor of Mannitol Inhalation Powder

On May 8th, 2019 the Pulmonary-Allergy Drugs Advisory Committee (PADAC) convened to review the new drug application (NDA) #202049 for Bronchitol (mannitol inhalation powder) sponsored by Chiesi USA, Inc. Bronchitol, an inhaled dry powder form of mannitol, is intended for the management of cystic fibrosis in adults to improve pulmonary function in conjunction with standard therapies.

Cystic fibrosis is a life-shortening genetic disease. An estimated 30,000 people in the United States are diagnosed with cystic fibrosis. This autosomal recessive disease is a multi-system disorder that affects the airways, exocrine pancreas, GI tract, and reproductive system. There is no cure for cystic fibrosis and current treatments are primarily aimed at management of respiratory complications.

Bronchitol is a sugar alcohol administered by a portable, easy-to use dry powder inhaler. The drug is a naturally occurring osmotic agent that improves lung function by increasing clearance of airway mucus. Three randomized, double blind, controlled phase 3 clinical studies evaluated Bronchitol for improvement in lung function.

Two discussion questions and three voting questions were presented to the committee. The FDA panel voted on whether the applicant provided substantial evidence of Bronchitol’s safety and efficacy in adult cystic fibrosis patients. The panel voted 9 YES to 7 NO. The vote was split for a variety of reasons. The panelists in support thought Bronchitol’s clinical program adequately demonstrated efficacy and addressed safety concerns. The members who voted “NO” were concerned with an increased risk of pulmonary exacerbations and the limited long-term data.

The agency is not obligated to follow its panels’ recommendation, but normally does so. The approval decision will be made in early 2020.

ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

This post was authored by Sharon Christian. Sharon is a summer intern at ISS and an undergraduate student at Rutgers University.

DO YOU HAVE AN UPCOMING ADVISORY COMMITTEE MEETING?

Download ISS' Essential Guide to Preparing for a Meeting at the FDA White Oak Campus.

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us